Solvent- and pH-Stable Eu(III)-Based Metal-Organic Framework with Phosphate-Ratio Fluorescence Sensing and Significant Proton Conduction.

Lanthanide-based metal-organic frameworks show good potential for applications due to their unique structures and functional properties. A highly thermally and acid-base stable was synthesized by a solvothermal method with the molecular formula {[(CH)NH][Eu(NDDP)(HO)]·HO} (, HNDDP = 5,5'-(naphthalene-2,6-diyl)diisophthalic acid). takes a three-dimensional (4,4,8)-connected topology.

Stable Europium(III) Metal-Organic Framework Demonstrating High Proton Conductivity and Fluorescence Detection of Tetracyclines.

A europium(III) metal-organic framework (MOF), namely, {[[(CH)NH]Eu(DTTP-2OH)(HCOO)(HO)]·4HO} (, HDTTP-2OH = 2',5'-dihydroxy-[1,1':4',1″-terphenyl]-3,3″,5,5″-tetracarboxylic acid) has been assembled through solvothermal method. The is a three-dimensional (3D) (4,4,8)-connected topological framework with binuclear Eu(III) clusters as secondary building units, in which a richly ordered hydrogen bonding network formed among the free HO molecules, dimethylamine cations, and phenolic hydroxyl groups provides a potential pathway for proton conduction. The proton conductivity reaches the category of superionic conductors (σ > 10 S cm) at room temperature with a maximum conductivity of 1.

Discovery and therapeutic implications of bioactive dihydroxylated phenolic acids in patients with severe heart disease and conditions associated with inflammation and hypoxia.

Our initial studies detected elevated levels of 3,4-dihydroxyphenyllactic acid (DHPLA) in urine samples of patients with severe heart disease when compared with healthy subjects. Given the reported anti-inflammatory properties of DHPLA and related dihydroxylated phenolic acids (DPAs), we embarked on an exploratory multi-centre investigation in patients with no urinary tract infections to establish the possible pathophysiological significance and therapeutic implications of these findings. Chinese and Caucasian patients being treated for severe heart disease or those conditions associated with inflammation (WBC ≥ 10 ×10/L or hsCRP ≥ 3.